192 related articles for article (PubMed ID: 34790980)
1. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.
Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960755
[TBL] [Abstract][Full Text] [Related]
3. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
Tada T; Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR
iScience; 2021 Nov; 24(11):103341. PubMed ID: 34723159
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
5. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
[TBL] [Abstract][Full Text] [Related]
6. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q.
Wilhelm A; Toptan T; Pallas C; Wolf T; Goetsch U; Gottschalk R; Vehreschild MJGT; Ciesek S; Widera M
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578275
[TBL] [Abstract][Full Text] [Related]
8. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera.
Li G; Zhou Z; Du P; Yu M; Li N; Xiong X; Huang H; Liu Z; Dai Q; Zhu J; Guo C; Wu S; Baptista-Hon DT; Miao M; Ming LW; Wu Y; Zeng F; Zhang CL; Zhang ED; Song H; Liu J; Lau JY; Xiang AP; Zhang K
Precis Clin Med; 2021 Sep; 4(3):149-154. PubMed ID: 35693215
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
10. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity.
Kuzmina A; Korovin D; Cohen Lass I; Atari N; Ottolenghi A; Hu P; Mandelboim M; Rosental B; Rosenberg E; Diaz-Griffero F; Taube R
Heliyon; 2023 Jun; 9(6):e16750. PubMed ID: 37292300
[TBL] [Abstract][Full Text] [Related]
11. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.
Lusvarghi S; Wang W; Herrup R; Neerukonda SN; Vassell R; Bentley L; Eakin AE; Erlandson KJ; Weiss CD
J Virol; 2022 Jan; 96(1):e0111021. PubMed ID: 34668774
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.
Cherian S; Potdar V; Jadhav S; Yadav P; Gupta N; Das M; Rakshit P; Singh S; Abraham P; Panda S; Team N
Microorganisms; 2021 Jul; 9(7):. PubMed ID: 34361977
[TBL] [Abstract][Full Text] [Related]
13. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
[TBL] [Abstract][Full Text] [Related]
14. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity.
Kuzmina A; Wattad S; Engel S; Rosenberg E; Taube R
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458533
[TBL] [Abstract][Full Text] [Related]
15. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.
Saunders N; Planas D; Bolland WH; Rodriguez C; Fourati S; Buchrieser J; Planchais C; Prot M; Staropoli I; Guivel-Benhassine F; Porrot F; Veyer D; Péré H; Robillard N; Saliba M; Baidaliuk A; Seve A; Hocqueloux L; Prazuck T; Rey FA; Mouquet H; Simon-Lorière E; Bruel T; Pawlotsky JM; Schwartz O
EBioMedicine; 2022 Mar; 77():103934. PubMed ID: 35290827
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
Tada T; Dcosta BM; Samanovic-Golden M; Herati RS; Cornelius A; Mulligan MJ; Landau NR
bioRxiv; 2021 Feb; ():. PubMed ID: 33564768
[TBL] [Abstract][Full Text] [Related]
17. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
18. Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity.
Zhang L; Li Q; Wu J; Yu Y; Zhang Y; Nie J; Liang Z; Cui Z; Liu S; Wang H; Ding R; Jiang F; Li T; Nie L; Lu Q; Li J; Qin L; Jiang Y; Shi Y; Xu W; Huang W; Wang Y
Emerg Microbes Infect; 2022 Dec; 11(1):1024-1036. PubMed ID: 35293847
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
Diamond M; Chen R; Xie X; Case J; Zhang X; VanBlargan L; Liu Y; Liu J; Errico J; Winkler E; Suryadevara N; Tahan S; Turner J; Kim W; Schmitz A; Thapa M; Wang D; Boon A; Pinto D; Presti R; O'Halloran J; Kim A; Deepak P; Fremont D; Corti D; Virgin H; Crowe J; Droit L; Ellebedy A; Shi PY; Gilchuk P
Res Sq; 2021 Feb; ():. PubMed ID: 33594356
[TBL] [Abstract][Full Text] [Related]
20. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
